Key result
Monoclonal IgM autoantibodies SCH94.03 and SCH94.32 promoted fourfold more CNS remyelination than controls in a mouse model of multiple sclerosis.
Why the study?
Do monoclonal autoantibodies promote CNS remyelination in an animal model of multiple sclerosis?
Population
SJL/J mice chronically infected with Theiler's murine encephalomyelitis virus
Comparison
Monoclonal IgM autoantibodies derived from… vs Controls
Design
Preclinical
Authors
Loading...
Supports remyelination by spinal cord-derived Ig in TMEV model; hypothesis-generating for MS, human trials required.
Do monoclonal autoantibodies promote CNS remyelination in an animal model of multiple sclerosis?
Effect estimate: fourfold increase
Monoclonal autoantibodies can promote CNS remyelination and halt clinical disease progression in a viral murine model of multiple sclerosis.
Miller et al. (1994) studied Multiple sclerosis (animal model). Monoclonal IgM autoantibodies (SCH94.03 and SCH94.32) vs. controls was evaluated on CNS remyelination (fourfold increase). Monoclonal IgM autoantibodies SCH94.03 and SCH94.32 promoted fourfold more CNS remyelination than controls in a mouse model of multiple sclerosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: